An exploratory study to evaluate the immune restoration after removal of viral antigen in patients with chronic hepatitis C virus treated with ombitasvir/oparitaprevir/ ritonavir + dasabuvir and ribavirin

Trial Profile

An exploratory study to evaluate the immune restoration after removal of viral antigen in patients with chronic hepatitis C virus treated with ombitasvir/oparitaprevir/ ritonavir + dasabuvir and ribavirin

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top